Sustained low-dose interleukin-2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus.

Kaili LiangJing HeYunbo WeiQunxiong ZengDongcheng GongJiahuan QinHuihua DingZhian ChenPing ZhouPeng NiuQian ChenChenguang DingLiangjing LuXiao-Xiang ChenZhanguo LiNan ShenDi YuJun Deng

Published in: Clinical & translational immunology (2021)

Low-dose IL-2 therapy increases the Tfr/Tfh ratio, and a less frequent and prolonged treatment can alleviate pathogenic humoral immunity and improve renal function.

Keyphrases

low dose
immune response
high dose
systemic lupus erythematosus
disease activity
mouse model
rheumatoid arthritis
mesenchymal stem cells
combination therapy
bone marrow